Skip to content

Menzies-Gow A, et al. Tezepelumab in adults and adolescents with severe uncontrolled asthma. N Engl J Med. 2021. PMID 33979488

One-paragraph summary

NAVIGATOR randomized 1,061 participants aged 12–80 with severe uncontrolled asthma to tezepelumab 210 mg or placebo every four weeks for 52 weeks. Annualized exacerbations were 0.93 (95% CI 0.80–1.07) versus 2.10 (1.84–2.39), rate ratio 0.44 (0.37–0.53). Among participants with blood eosinophils below 300 cells/µL, rates were 1.02 versus 1.73, rate ratio 0.59 (0.46–0.75). Pre-bronchodilator FEV1 improved by 0.13 L (0.08–0.18) more than placebo.

Key findings

  • Blocking the upstream epithelial alarmin TSLP reduced attacks in a broad severe-asthma population.
  • Benefit remained demonstrable below a 300-cell/µL eosinophil threshold.
  • Average ACQ-6 and AQLQ between-group improvements were 0.33 and 0.34 points, smaller than conventional individual minimal-important-difference values despite a large attack effect.

Limitations

  • “Across biomarker strata” does not mean identical absolute or relative benefit in every low-marker subgroup.
  • Background adherence was trial-supported; real-world eligibility and cost change net benefit.
  • One year cannot establish remodeling reversal, remission or optimal withdrawal.

Why it matters

NAVIGATOR broadened severe-asthma targeting beyond classic downstream type-2 eligibility. It also reinforces the recurring asthma pattern that attack prevention can be clinically large while average symptom/quality-of-life differences are more modest.

Cited by wiki pages

  • overview
  • severe asthma and biologics
  • clinical trials landscape